Circulating Tumor Cells Industry Overview
The global Circulating Tumor Cells market size was valued at USD 8.4 billion in 2020 is expected to expand at a compound annual growth rate (CAGR) of 11.7% from 2021 to 2027. Owing to the non-invasiveness and advantages offered by circulating tumor cells, it is considered a promising tool in cancer diagnosis. In addition, technological advancements in chip technology are another key factor driving the market. Since the last several decades, extensive translational and clinical cancer research programs in the field of circulating tumor cells (CTCs) are being conducted. The ongoing research on circulating tumor cells technology by several government bodies, such as the American Association of Cancer Research and the American Society of Clinical Oncology, to utilize circulating tumor cells as a surrogate marker for determination of cancer progression is expected to aid the growth of the market.
Several tumor markers that have been introduced in recent years can be used with companion diagnostics to monitor or diagnose a variety of cancers. High adoption of companion diagnostics in monitoring tumor eradication characteristics of cytotoxic drugs is among the few factors propelling the demand in this market. Key stakeholders are constantly engaged in endeavors aimed at developing CTC-based tests, which can prove helpful in cancer diagnosis.
Gather more insights about the market drivers, restraints, and growth of the Global Circulating Tumor Cells market
Concerns related to the reliability and consistency of isolation as well as the relationship between quantitation of this biomarker and cancer prognosis are limiting factors affecting the clinical utility of this biomarker. Although there is a wide availability of several benchtop instruments for analysis and delineating circulating tumor cells from other blood cells, it is difficult to characterize these cells due to substantial phenotypes exhibited by these cells.
Furthermore, this biomarker has long been a subject of academic research, but the difficulty of centralizing the know-how and technologies has obscured the path to commercialization as many universities and private companies have developed their own expertise. However, recent years have seen a drive toward practical application, majorly due to a wave of acquisitions by large players centralizing the technology and numerous tie-ups with pharmaceutical companies to make progress toward forming a value chain and accelerate the market growth.
Browse through Grand View Research's Biotechnology Industry Research Reports
Cell Culture Market - The global cell culture market size was valued at USD 21.05 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 11.9% from 2022 to 2030.
Single-cell Analysis Market - The global single-cell analysis market size was valued at USD 3.28 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 18.5% from 2022 to 2030.
Market Share Insights:
November 2019: Biolidics Limited signed an agreement with Sysmex Corporation to develop a laboratory-developed test for the diagnosis of cancer. Since 2016, the companies collaborated for R&D of laboratory assays in this field by using ClearCell FX1 System along with Sysmex’s MI-FCM, a molecular imaging flow cytometer. This extension in collaboration helped the company expand its product portfolio.
Key Companies profiled:
Some prominent players in the global Circulating Tumor Cells market include
- QIAGEN
- Bio-Techne Corporation
- Precision for Medicine
- AVIVA Biosciences
- BIOCEPT, Inc.
- BioCEP Ltd.
- Fluxion Biosciences, Inc.
- Greiner Bio One International GmbH
- Ikonisys Inc.
- Miltenyi Biotec
- IVDiagnostics
Order a free sample PDF of the Circulating Tumor Cells Market Intelligence Study, published by Grand View Research.
No comments:
Post a Comment